University of Vermont Cancer Center Member Profile
Diego Adrianzen Herrera, MD
Associate Professor, Medicine
Assistant Professor, Medicine-Hematology OncologyAssociate Professor, Medicine-Hematology Oncology
Full Member
Cancer and Host Interactions (CHI)
Academic Interests
Dr. Adrianzen Herrera's research focuses on health outcomes and translational epidemiology of hematologic malignancies, with special focus on myeloid cancer. This includes large population database and administrative claims analysis to study outcomes among patients with myelodysplastic syndromes and acute myeloid leukemia. He is also exploring proteomic data to identify biomarkers of cardiovascular disease in patients with myelodysplastic syndromes.
Other Titles, Distinctions and Appointments
Dr. Adrianzen-Herrera is a scholar of the American Society of Hematology’s Clinical Research Training Institute and was named the UVM’s Department of Medicine Green and Gold Early Career Professor in 2021.
Postdoctoral Training
2019..... Hematology & Medical Oncology Fellowship, Albert Einstein College of Medicine, New York
2016..... Internal Medicine Residency, Ichan School of Medicine at Mount Sinai, New York
Education
2011..... Cayetano Heredia University, Lima, Peru; MD
Publications
To view more and/or the most recent publications by Diego Adrianzen Herrera please visit their bibliography here.
Characteristics and survival of secondary acute myeloid leukemia arising from myelodysplastic syndrome (MDS-sAML).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19075-e19075
Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
AH Bazarbachi, D Reef, H Narvel, R Patel, R Al Hamed, S Vikash, ...
Clinical Hematology International, 1-14
Effect of hypomethylating agent (HMA) exposure on survival of secondary acute myeloid leukemia (sAML) from myelodysplastic syndrome (MDS).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19076-e19076
Dr. Adrianzen Herrera's research focuses on health outcomes and translational epidemiology of hematologic malignancies, with special focus on myeloid cancer. This includes large population database and administrative claims analysis to study outcomes among patients with myelodysplastic syndromes and acute myeloid leukemia. He is also exploring proteomic data to identify biomarkers of cardiovascular disease in patients with myelodysplastic syndromes.
Other Titles, Distinctions and Appointments
Dr. Adrianzen-Herrera is a scholar of the American Society of Hematology’s Clinical Research Training Institute and was named the UVM’s Department of Medicine Green and Gold Early Career Professor in 2021.
Postdoctoral Training
2019..... Hematology & Medical Oncology Fellowship, Albert Einstein College of Medicine, New York
2016..... Internal Medicine Residency, Ichan School of Medicine at Mount Sinai, New York
Education
2011..... Cayetano Heredia University, Lima, Peru; MD
Publications
To view more and/or the most recent publications by Diego Adrianzen Herrera please visit their bibliography here.
Characteristics and survival of secondary acute myeloid leukemia arising from myelodysplastic syndrome (MDS-sAML).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19075-e19075
Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
AH Bazarbachi, D Reef, H Narvel, R Patel, R Al Hamed, S Vikash, ...
Clinical Hematology International, 1-14
Effect of hypomethylating agent (HMA) exposure on survival of secondary acute myeloid leukemia (sAML) from myelodysplastic syndrome (MDS).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19076-e19076